(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Background: Although recent studies provide insight into the molecular mechanisms of the effects of ketamine, the antidepressant mechanism of ketamine enantiomers and their metabolites is not fully understood. In view of the involvement of mechanisms other than the N-methyl-D-aspartate receptor in ketamine’s action, we investigated the effects of (R)-ketamine, (S)-ketamine, (R)-norketamine [(R)-NK], (S)-NK, (2R,6R)-hydroxynorketamine [(2R,6R)-HNK], and (2S,6S)-HNK on monoaminergic neurotransmission in the prefrontal cortex of mice. Methods: The extracellular monoamine levels in the prefrontal cortex were measured by in vivo microdialysis. Results: (R)-Ketamine and (S)-ketamine acutely increased serotonin release in a dose-dependent manner, and the effect of (R)-ketamine was greater than that of (S)-ketamine. In contrast, (S)-ketamine caused a robust increase in dopamine release compared with (R)-ketamine. Both ketamine enantiomers increased noradrenaline release, but these effects did not differ. (2R,6R)-HNK caused a slight but significant increase in serotonin and noradrenaline but not dopamine release. (S)-NK increased dopamine and noradrenaline but not serotonin release. Differential effects between (R)-ketamine and (S)-ketamine were also observed in a lipopolysaccharide-induced model of depression. An α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4- tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX), attenuated (S)-ketamine-induced, but not (R)-ketamine-induced serotonin release, whereas NBQX blocked dopamine release induced by both enantiomers. Local application of (R)-ketamine into the prefrontal cortex caused a greater increase in prefrontal serotonin release than that of (S)-ketamine. Conclusions: (R)-Ketamine strongly activates the prefrontal serotonergic system through an AMPA receptor-independent mechanism. (S)-Ketamine-induced serotonin and dopamine release was AMPA receptor-dependent. These findings provide a neurochemical basis for the underlying pharmacological differences between ketamine enantiomers and their metabolites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The effects of (R)-ketamine, (S)-ketamine, and their metabolites on extracellular serotonin (5-HT) (A), dopamine (DA) (B), and noradrenaline (NA) (C) levels in the prefrontal cortex (PFC) of mice. (R)-ketamine (10, 20 mg/kg), (S)-ketamine (10, 20 mg/kg), (R)-norketamine [(R)-NK] (20 mg/kg), (S)-NK (20 mg/kg), (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] (20 mg/kg), (2S,6S)-HNK (20 mg/kg), or saline was i.p. injected at 0 minutes (arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with the saline-treated mice at each time point.](https://figures.cochat.ai/paper-figures/621c9bec90704718a8ce98eb7722bd3b/r-ketamine-induces-a-greater-increase-in-prefrontal-5-ht-release-than-s-ketamine-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For dopamine, (R)-ketamine (20 mg/kg) resulted in only modest changes, with a modest increase 40 minutes post-injection.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For serotonin, (R)-ketamine (10 and 20 mg/kg i.p.) produced an increase at 20-, 40-, and 60-minutes post-treatment with a peak effect size at ~275% of baseline following a 20 mg/kg dose at 20 minutes.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“(2R,6R)-HNK (20 mg/kg) increased serotonin at 40- and 60-minutes post-treatment with a peak effect at ~140% of baseline whereas (2S,6S)-HNK and (R) and (S)-norketamine (20 mg/kg) were ineffective.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peak increases in dopamine by (R)-ketamine and peak increases in serotonin and dopamine by (S)-ketamine are prevented by the AMPAR antagonist NBQX pretreatment 20 minutes prior.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“norepinephrine levels were significantly impacted by (R)-ketamine (20 mg/kg) with a peak effect size of ~160% of baseline 40 minutes post-treatment and remained heightened following 120 minutes”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,437
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
Guide for the care and use of laboratory animals
(1997) · Choice Reviews Online · doi:10.5860/choice.34-3310 · Cited by 2,922
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 2×
“Several molecular mechanisms underlying the antidepressant-like effects of ketamine have been proposed, especially focusing on the glutamatergic system such as synaptic or GluN2B-selective extra-synaptic NMDA receptor inhibition, inhibition of NMDA receptors localized on GABAergic interneurons, and the role of α-amino…”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 3×
“Since the AMPA receptor is suggested to be involved in the antidepressant-like effects of ketamine (Maeng et al., 2008; Chaki, 2017; Pałucha-Poniewiera, 2018; Zanos and Gould, 2018; Duman et al., 2019), we subsequently examined the effects of 2,3-dioxo-6-nitro-1,2,3,4- tetrahydrobenzo[f] quinoxaline-7-sulfonamide (NBQ…”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“Accumulating evidence has indicated that the N-methyl-Daspartate (NMDA) receptor antagonist ketamine (racemic ketamine; (R,S)-ketamine) has rapid and potent antidepressant effects in major depressive disorder including treatment-resistant depression (Berman et al., 2000; Zarate et al., 2006a; Murrough et al., 2013; Ne…”
Background
Cited by
Ketamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
“Furthermore, although (S)-ketamine has been shown to cause a robust increase in dopamine release compared with (R)-ketamine, the antidepressant-like effects were more potent and longer acting following (R)-ketamine administration in a mouse model (Ago et al., 2019).”
BackgroundResultPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Self-citationMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
A historical review of antidepressant effects of ketamine and its enantiomers
Wei, Y., Chang, L., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172870 · Cited by 157
Self-citationWojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Szych, Z., Majcher‐Maślanka, I., Herian, M., Maćkowiak, M., & Gołembiowska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126713 · Cited by 119
“AMPA receptors might be also involved in regulating ketamine-induced DA release in the prefrontal cortex as the AMPA receptor antagonist NBQX blocks the effects of ketamine on DA release [39].”
BackgroundClaustrum mediates bidirectional and reversible control of stress-induced anxiety responses
Niu, M., Kasai, A., Tanuma, M., Seiriki, K., Igarashi, H., Kuwaki, T., Nagayasu, K., Miyaji, K., Ueno, H., Tanabe, W., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi6375 · Cited by 100
“Forced swim test The forced swim test was conducted by placing the mice into an individual acrylic cylinder (25 cm height by 19 cm diameter) containing 25° ± 1°C water at a depth of 13 cm, as described previously (66).”
MethodSelf-citationHydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000149 · Cited by 92
“) (Pham et al., 2018; Ago et al., 2019) and norepinephrine (20 mg/kg, i.”
BackgroundInfluentialKetamine treatment for refractory anxiety: A systematic review
Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15374 · Cited by 104
“These actions are largely attributed to AMPA receptor-dependent synaptic transmission and the release of neurotransmitters such as serotonin and norepinephrine.(51) While initial reports claim that the antidepressant-effects of (2R,6R)-HNK are independent of the NMDA receptor,(50,52) others show that higher concentrat…”
BackgroundTiger, M., Veldman, E. R., Ekman, C.-J., Halldin, C., Svenningsson, P., & Lundberg, J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0844-4 · Cited by 81
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Yokoyama, R., Higuchi, M., Tanabe, W., Tsukada, S., Naito, M., Yamaguchi, T., Chen, L., Kasai, A., Seiriki, K., Nakazawa, T., et al. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172876 · Cited by 65
Self-citationNeurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities
Shinohara, R., Aghajanian, G. K., & Abdallah, C. G. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.006 · Cited by 54
Wang, Y., Zhang, N., Liu, L., Jiang, H., Hu, D., Wang, Z., Chen, N., & Zhang, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.024 · Cited by 52
Rafało-Ulińska, A., & Pałucha-Poniewiera, A. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113633 · Cited by 45
Jiang, C. S., Dileone, R., Pittenger, C., & Duman, R. S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02796-0 · Cited by 92
“…[42, 43], leading to increased release of β -endorphin from the axon terminals of ARC POMC neurons in the mPFC [44]; this is similar to ketamine-induced release of dopamine, serotonin and noradrenaline [42, 45, 46], which all show rapid elevation within an hour following ketamine administration.”
BackgroundPassie, T., Adams, H.-A., Logemann, F., Brandt, S. D., Wiese, B., & Karst, M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.01.005 · Cited by 49
“Preclinical research on antidepressant effects of ketamine indicates that ( R )-ketamine strongly activates the prefrontal serotonergic system through an AMPA receptor-independent way, whilst ( S )-ketamine induces both, serotonin and dopamine release AMPA receptor-dependently ( Ago et al., 2019 ).”
St. Johnʼs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?
Kholghi, G., Arjmandi-Rad, S., Zarrindast, M., & Vaseghi, S. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02229-z · Cited by 57
Witkin, J. M., Kranzler, J., Kaniecki, K., Popik, P., Smith, J. L., Hashimoto, K., & Sporn, J. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172927 · Cited by 38
Self-citationScotton, E., Antqueviezc, B., Vasconcelos, M., Dalpiaz, G., Géa, L. P., Goularte, J. F., Colombo, R., & Rosa, A. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114963 · Cited by 40
Bowman, M. A., Vitela, M., Clarke, K. M., Koek, W., & Daws, L. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207581 · Cited by 33
“Of course, because ketamine was delivered systemically in these behavioral studies, a role for metabolites of ketamine cannot be ruled out [20,41,46,49].”
BackgroundThe role of serotonin neurotransmission in rapid antidepressant actions
Pehrson, A. L., Roberts, D., Khawaja, A., & McNair, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06098-5 · Cited by 37
Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review
Song, B., & Zhu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.782457 · Cited by 32
A Novel Application of Ketamine for Improving Perioperative Sleep Disturbances
Song, B., & Zhu, J. (2021) · Nature and Science of Sleep · doi:10.2147/nss.s341161 · Cited by 33
Rafało-Ulińska, A., Brański, P., & Pałucha-Poniewiera, A. (2022) · Pharmaceuticals · doi:10.3390/ph15020125 · Cited by 29
“These differences include various affinities for the NMDA receptor complex [16], different effects on the regulation of monoamine release in various brain structures [17], involvement in various molecular mechanisms [18] and different therapeutic potentials, such as (R)-ketamine exhibiting a longer-lasting and stronge…”
BackgroundBeating pain with psychedelics: Matter over mind?
Elman, I., Pustilnik, A. C., & Borsook, D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.005 · Cited by 30
Koncz, S., Papp, N., Pothorszki, D., & Bagdy, G. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad050 · Cited by 32
“Interestingly, both ketamine enantiomers (both 10 and 20 mg/kg i.p.) acutely increased serotonin release in the pre-frontal cortex (PFC) of mice, but the effects of (R)-ketamine were greater than that of (S)-ketamine (Ago et al., 2019).”
Sales, A. J., Maciel, I. D. S., Suavinha, A. C. D. R., & Joca, S. R. L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02145-4 · Cited by 31
Ma, S., Dou, Y., Wang, W., Wei, A., Lan, M., Liu, J., Yang, L., & Yang, M. (2024) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2023.101241 · Cited by 30
Tarrés-Gatius, M., Miquel-Rio, L., Campa, L., Artigas, F., & Castañé, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01110-y · Cited by 29
Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites
Ago, Y., Yokoyama, R., Asano, S., & Hashimoto, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109313 · Cited by 26
Self-citationWojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010100 · Cited by 30
Yokoyama, R., Ago, Y., Igarashi, H., Higuchi, M., Tanuma, M., Shimazaki, Y., Kawai, T., Seiriki, K., Hayashida, M., Yamaguchi, S., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02419-6 · Cited by 28
“Furthermore, ( R )-ketamine induces serotonin release in the prefrontal cortex, whereas ( S )-ketamine induces dopamine release, indicating differences in pharmacological effects between the two enantiomers [34].”
BackgroundSelf-citationPapp, M., Gruca, P., Łasoń, M., Litwa, E., Solecki, W., & Willner, P. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120967857 · Cited by 23
“, 2008), although alternative mechanisms are also under consideration (Ago et al., 2019; Aleksandrova et al., 2017; Kadriu et al., 2019; Yang et al., 2019).”
BackgroundKetamine, benzoate, and sarcosine for treating depression
Cheng, Y., Lin, C., & Lane, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109351 · Cited by 21
Yin, Y., Yan, J., Wei, Q., Sun, S., Ding, Y., Zhang, L., & Li, Y. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17324 · Cited by 20
“Although acute ketamine administration (60 min) led to increased brain 5-HT levels in our study and in others (Ago et al., 2019; Viana et al., 2018), this initial increase in brain 5-HT levels might not be responsible for its rapid antidepressant-like behavioural effects.”
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation
Mitchell, J., Hermens, D. F., Bennett, M. R., Can, A., & Lagopoulos, J. (2023) · CNS Drugs · doi:10.1007/s40263-022-00984-4 · Cited by 23
“Notably, the effect of ketamine on the 5-HT systems is stereoisomer and metabolite specific [201].”
BackgroundTargeting the dysfunction of glutamate receptors for the development of novel antidepressants
Xia, C., He, J., Du, L., Yan, Y., Lian, W., Xu, J., & Zhang, W. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107875 · Cited by 15
Jiang, Q., Qi, Y., Zhou, M., Dong, Y., Zheng, W., Zhu, L., Li, Y., Zhou, H., & Wang, L. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02681-9 · Cited by 14
“Another important pathway mediating the antidepressant effects of esketamine is the activation of monoam-inergic receptors and increased release of monoamine transmitters such as 5-HT and DA [8, 9].”
BackgroundCYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Riggs, L. M., Thompson, S. M., & Gould, T. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109153 · Cited by 16
Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications
Zhang, S., Pu, Y., Liu, J., Li, L., An, C., Wu, Y., Zhang, W., Zhang, W., Qu, S., & Yan, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1337749 · Cited by 18
Wang, Y., Zhang, Y., Wang, K., Zhu, Z., Wang, D., Yang, Q., & Dong, H. (2022) · Journal of Neurophysiology · doi:10.1152/jn.00462.2021 · Cited by 12
Spike firing attenuation of serotonin neurons in learned helplessness rats is reversed by ketamine
Hashimoto, K., Yamawaki, Y., Yamaoka, K., Yoshida, T., Okada, K., Tan, W., Yamasaki, M., Makidono, Y., Kubo, R., Nakayama, H., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab285 · Cited by 11
“Previous reports demonstrated that the acute administration of ketamine, which shows rapid antidepressant effects, 47,48 enhances the 5-HT level in the prefrontal cortex 49–54 and the hippocampus.”
Self-citationThe Role of Gut Microbiota in the Antidepressant Effects of Ketamine
Wang, Y., Xu, X., Luo, A., & Yang, C. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_8 · Cited by 10
Kambe, Y., Yamauchi, Y., Nguyen, T. T., Nguyen, T. T., Ago, Y., Shintani, N., Hashimoto, H., Yoshitake, S., Yoshitake, T., Kehr, J., et al. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00222-6 · Cited by 12
“Microdialysis experiments were performed as previously described [27].”
MethodSelf-citationElwyn, R., Mitchell, J., Kohn, M. R., Driver, C., Hay, P., Lagopoulos, J., & Hermens, D. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105122 · Cited by 11
Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic
Quintero, J.-M., Bustos, R., Lechtig, S., Beltran, S., & Zarate, C. A. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.007 · Cited by 13
Colla, M., Scheerer, H., Weidt, S., Seifritz, E., & Kronenberg, G. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.759466 · Cited by 13
“Microdialysis studies have demonstrated increased serotonin release by ketamine in the rodent prefrontal cortex (Ago et al., 2019; López-Gil et al., 2019).”
BackgroundNguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
“(R)-ketamine strongly activates the prefrontal serotonergic system through an AMPA-receptor-independent mechanism, while (S)-ketamine-induced serotonin and dopamine release are activated through the AMPA-receptor-dependent mechanism [124].”
Esketamine Inhibits Cocaine-Seeking Behaviour Subsequent to Various Abstinence Conditions in Rats
Wydra, K., Witek, K., Suder, A., & Filip, M. (2023) · Biomolecules · doi:10.3390/biom13091411 · Cited by 9
“Such effects might be linked with esketamine-induced increases in DA release [7] and reduced DA D2/3 receptor binding in the striatum [13].”
BackgroundSubanesthetic ketamine exerts antidepressant-like effects in adult rats exposed to juvenile stress
Aikawa, K., Yoshida, T., Ohmura, Y., Lyttle, K. A., Yoshioka, M., & Morimoto, Y. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146980 · Cited by 8
Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia
Maraschin, J. C., Frias, A. T., Hernandes, P. M., Batistela, M. F., Martinez, L. M., Joca, S. R. L., Graeff, F. G., Audi, E. A., de Andrade, T. G. C. S., & Zangrossi, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113651 · Cited by 8
Camargo, A., Nilsson, A., Shariatgorji, M., Appleton, E., Branzell, N., Doyon, D., Giovenzana, M., Zhang, X., Dautan, D., Andrén, P. E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02853-6 · Cited by 11
Suicide prevention and ketamine: insights from computational modeling
Charlton, C. E., Karvelis, P., McIntyre, R. S., & Diaconescu, A. O. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1214018 · Cited by 7
Unique Effects of (R)-Ketamine Compared to (S)-Ketamine on EEG Theta Power in Rats
Pothorszki, D., Koncz, S., Török, D., Papp, N., & Bagdy, G. (2024) · Pharmaceuticals · doi:10.3390/ph17020194 · Cited by 8
“(R)-ketamine has also been proposed to induce greater serotonin (5-HT) release in the PFC compared to (S)-ketamine [25], although no difference was found between the two enantiomers’ binding affinity to 5-HT receptors [3], suggesting that higher 5-HT concentration may explain the stronger effect of…”
ResultA synopsis of multitarget therapeutic effects of anesthetics on depression
Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 7
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
“It is unlikely that direct affinity of ketamine to serotonergic proteins is of central relevance [98] but rather that effects on glutamate impact serotonergic neurotrans-mission, e.g., via an AMPA-dependent mechanism [99].”
Matar, D., Serhan, A., Bilani, S. E., Faraj, R. A., Hadi, B. A., & Fakhoury, M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_2 · Cited by 7
Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats
Davis-Reyes, B. D., Smith, A. E., Xu, J., Cunningham, K. A., Zhou, J., & Anastasio, N. C. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000623 · Cited by 7
“Taken together, it is wholly possible that neurochemical alterations induced by ketamine administration, such as enhanced release of serotonin (5-HT), dopamine, and Glu (Lindefors et al., 1997; Chatterjee et al., 2012; Ago et al., 2019), impacts the neural circuitry that encodes incentive salience.”
BackgroundMastrodonato, A., Jin, M., Kee, N., Lanio, M., Tapia, J., Quintana, L., Zamora, A., Deng, S., Xu, X., Landry, D. W., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.09.024 · Cited by 7
de Oliveira, E. G., de Lima, D. A., Júnior, J. C. D. S., Barbosa, M. V. D. S., Silva, S. C. D. A., de Santana, J. H., dos Santos, O. H., Lira, E. C., Lagranha, C. J., Duarte, F. S., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01629-3 · Cited by 6
“injections and the doses employed were chosen from previous studies [2, 3, 41].”
MethodPleiotropic modulation of the gut-brain-lung axis by ketamine and its enantiomers
Zhao, X., Zhang, X., Yuan, S., Hashimoto, K., & Zhang, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03590-8 · Cited by 6
Self-citationLa kétamine : un neuropsychotrope au mécanisme d’action innovant
Guilloux, J., Nguyen, T. M. L., & Gardier, A. M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023026 · Cited by 5
Beneficial effects of Esketamine on Morphine preference reacquisition in male rats
Fontoura, M. B., da Rosa, J. L. O., Rossato, D. R., de Souza, L. E. M., Frozi, E., Ribeiro, M. E. M., de Souza, A. R., & Bürger, M. E. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.011 · Cited by 4
Rached, G., Campana, A. M., Fiani, D., Nguyen, C. Y., den Eynde, V. V., Gillman, P. K., & Barnett, B. S. (2026) · CNS Drugs · doi:10.1007/s40263-025-01256-7 · Cited by 3
Zaccarelli‐Magalhães, J., Abreu, G. R., Fukushima, A. R., Pantaleon, L. D. P., Ribeiro, B. B., Munhoz, C., Manes, M., de Lima, M. A., Miglioli, J., Flório, J. C., et al. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114799 · Cited by 3
Sasaki, U., Irifune, M., Kochi, T., Tomohiro, M., Nakamura, Y., Imado, E., Oda, A., Kamio, H., Imamura, S., Oue, K., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178068 · Cited by 3
Self-citationDrozd, U. S., Lanshakov, D. A., & Дыгало, Н. Н. (2023) · Neurochemical Journal · doi:10.1134/s181971242303008x · Cited by 4
TREK-1 channel blockade mediates the antidepressant-like effects of hydroxynorketamine
Song, Y., Song, Y., Du, W., Yu, X., Li, Y., Chang, L., Huang, X., Ye, B., Li, T., Li, Y., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110751 · Cited by 2
Valentino, K., Ballum, H., Cheung, W., Dri, C. E., Teopiz, K. M., Kwan, A. T. H., Wong, S., Shen, B., Cheng, M. C. H., Le, G. H., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.02.011 · Cited by 2
Coutellier, L. D., Musazzi, L., & Pavlovic, Z. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_4 · Cited by 2
Can ketamine and other glutamate receptor modulators be considered entactogens?
Hu, H., Tillman, A. N., Fujita, M., Yoshikawa, M., Ballard, E. D., Lee, Y., & Zarate, C. A. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116513 · Cited by 3
Ding, J., Yang, Y., Cao, D., Wang, T., & Yu, Q. (2025) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16311 · Cited by 3
“20 Ago et al., 21 in particular, found that esketamine could promote 5-HT release in the prefrontal cortical layer in a dose-dependent manner.”
Szawarnoga, D., Fojcik, J., Górski, M. K., Pałasz, A., & Krzystanek, M. (2025) · Pharmaceuticals · doi:10.3390/ph18071066 · Cited by 4
“Both enantiomers of ketamine increased the level of noradrenaline in this brain region [22].”
Mechanism of antidepressant action of ketamine and differences between its two enantiomers
Zhan, J., Zhang, Y., Tian, H., Zhu, X., Guo, M., Qiu, Z., & Xia, Z. (2025) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2025.06.001 · Cited by 1
“188 5-HT depletion eliminated the antidepressant effects of S-ke-tamine in a genetic model of depression, 189 but it did not alter the antidepressant effects of R-ketamine in CSDS model, 190 suggesting that 5-HT may not play a major role in the antidepressant effects of R-ke-tamine.”
Sun, Y., Li, B., Wang, Y., Jiang, X., Tang, S., Zhang, J., & Zhang, J. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111648 · Cited by 1
Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study
Wani, Z. A., Raj, R., Dar, S. A., & Haq, I. (2026) · Indian Journal of Psychological Medicine · doi:10.1177/02537176251415001 · Cited by 2
“3 In addition, it induces serotonin and dopamine release via multiple mechanisms, 12 regulates synaptic plasticity and forms excitatory synapses, resulting in an immediate response.”
Kétamine et suicidalité : modèles animaux pour comprendre son mécanisme d’action
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2023.10.008 · Cited by 2
Perspective Chapter: Ketamine, Depression, and Gender Bias
Alshammari, T. K., Alseraye, S., Al-Rasheed, N. M., Dayel, A. F. B., Alonazi, A. S., Sabhan, J. F. A., & Alshammari, M. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103656
Schnell wirksame Antidepressiva
Şen, Z. D., Danyeli, L. V., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_10
Kasai, A., Yokoyama, R., Ago, Y., Igarashi, H., Higuchi, M., Tanuma, M., Shimazaki, Y., Seiriki, K., Hayashida, M., Yamaguchi, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3305430/v1
Self-citationDrozd, U. S., Lanshakov, D. A., & Дыгало, Н. Н. (2023) · Нейрохимия · doi:10.31857/s1027813323030081
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
de Oliveira, E. G., Barbosa, M. V. D. S., de Lima, D. A., Júnior, J. C. D. S., Silva, S. C. D. A., de Santana, J. H., Júnior, O. H. D. S., Lira, E. C., Lagranha, C. J., Duarte, F. S., et al. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06974-w
“Dosing levels and time courses of ketamine were chosen from our preliminary studies derived from in vivo behavioral studies carried out by other authors (Parise et al. 2013; Ago et al. 2019).”
Pantoja, L. V. P. D. S., Soares, L. F. R., da Conceição, B. C., Carvalheiro-Simas, T. C. V. S., Luz, D. A., Prediger, R. D., de Andrade, G. M., Fontes-Júnior, E. A., Pinheiro, B. G., Cartágenes, S. D. C., et al. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116048
Chan-Monroy, J. M., Estrada-Camarena, E. M., & López‐Rubalcava, C. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178705
Ketamine in clinical psychiatry and addictology - a narrative review
Vašíček, O., & Páleníček, T. (2026) · Psychiatrie pro praxi · doi:10.36290/psy.2026.004
Wei, X., Xu, S., & Zhu, Z. (2026) · Current Neuropharmacology · doi:10.2174/011570159x458197260226055817
“[22] examined the effects of ketamine and its metabolites on monoamine neurotransmitters in the prefrontal cortex (PFC) using microdialysis.”
Matheson, G. J., Lundberg, J., Gärde, M., Veldman, E. R., Tateno, A., Ekman, C., Arakawa, R., Knudsen, G. M., Okubo, Y., Ogden, R. T., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03704-2
Xiao, C., Xu, X., Yao, W., Pan, Y., Wan, S., Wei, J., & Xu, L. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.10.038
Metadata
- Authors
- Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., Nakazawa, T., Nakagawa, S., Hashimoto, K., & Hashimoto, H.
- Affiliations
- The University of Osaka (JP)
- Kanazawa University (JP)
- Corresponding author
- Ago, Yukio
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-21
- Volume
- 22
- Issue
- 10
- Pages
- 665-674
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822138
- OpenAlex
- W2966617845
- Cited by
- 92
- References
- 71
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 11 · 2023: 16 · 2022: 15 · 2021: 15 · 2020: 13 · 2019: 1
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (JP16K08268, JP17K19488, JP17H03989)
- Ministry of Education, Culture, Sports, Science and Technology (JP18H05416, JP19dm0107122, JP19dm0207061, JP19dm0107119)
- Takeda Science Foundation
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine enantiomers, (R)-ketamine, esketamine, ketamine metabolites, norketamine, hydroxynorketamine, serotonin release, dopamine release, noradrenaline release, prefrontal cortex, AMPA receptors, NBQX, antidepressant mechanism, lipopolysaccharide-induced depression, monoaminergic neurotransmission
- MeSH terms
- Animals, Disease Models, Animal, Dopamine, Dose-Response Relationship, Drug, Ketamine, Lipopolysaccharides, Male, Microinjections, Norepinephrine, Quinoxalines, Serotonin, Stereoisomerism, Prefrontal Cortex, Microdialysis, Receptors, AMPA, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.